Evaluation of the National Treatment Program of Hepatitis C in Egypt

Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)

NCT00158522 ·Status: COMPLETED ·Phase: PHASE3

Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients

NCT01197157 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages

NCT04177043 ·Status: COMPLETED ·Phase: PHASE4

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

NCT02771405 ·Status: COMPLETED ·Phase: PHASE3

Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?

NCT04757272 ·Status: COMPLETED

24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C

NCT01517308 ·Status: WITHDRAWN ·Phase: PHASE3

Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients

NCT03341988 ·Status: COMPLETED ·Phase: PHASE1

Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C

NCT01327729 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

NCT00418639 ·Status: COMPLETED ·Phase: PHASE2

Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

NCT00277862 ·Status: COMPLETED ·Phase: PHASE4

Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

NCT02247401 ·Status: COMPLETED ·Phase: PHASE3

Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV

NCT02027493 ·Status: COMPLETED ·Phase: NA

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644 ·Status: COMPLETED ·Phase: PHASE2

A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

NCT00790673 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C

NCT00763568 ·Status: COMPLETED ·Phase: PHASE2

Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4

NCT02772744 ·Status: UNKNOWN

Timing and Duration of Acute Hepatitis C Treatment

NCT00241618 ·Status: COMPLETED ·Phase: PHASE4

Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs

NCT02532907 ·Status: COMPLETED

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

NCT03163849 ·Status: UNKNOWN ·Phase: PHASE3

Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)

NCT01121705 ·Status: COMPLETED ·Phase: PHASE3

Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV

NCT03069001 ·Status: COMPLETED ·Phase: PHASE4

Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

NCT01226797 ·Status: TERMINATED ·Phase: PHASE2

Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1

NCT02629172 ·Status: COMPLETED

Control and Elimination Within Australia of Hepatitis C From People Living With HIV

NCT02102451 ·Status: UNKNOWN

Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus

NCT03540212 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3